Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital

Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital

ABSTRACT Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity against Gram-positive organisms. Dalbavancin is Food and Drug Administration (FDA)-approved for acute bacterial skin and soft tissue infections (ABSSTIs). There is a lack of substantial data on dalbavancin in more...

Full description

Bibliographic Details
Main Authors: Richard Lueking, Wenjing Wei, Norman S. Mang, Jessica K. Ortwine, Jessica Meisner
Format: Article
Language:English
Published: American Society for Microbiology 2023-02-01
Series:Microbiology Spectrum
Subjects:
dalbavancin
antibiotics
Gram-positive bacteria
infectious disease
lipoglycopeptides
Online Access:https://journals.asm.org/doi/10.1128/spectrum.02385-22

Internet

https://journals.asm.org/doi/10.1128/spectrum.02385-22

Similar Items